MicroPort Medical announced its acquisition of 72.37% equity in Optimum Medical, making it a wholly-owned subsidiary.

On July 1, 2024, Shanghai MicroPort Medical (Group) Co., Ltd. (hereinafter referred to as "MicroPort Medical") issued a notice titled "Announcement on Acquisition of Equity Interest in Optimum Medical Device Inc.", announcing its plan to acquire 72.37% equity interest in Optimum Medical Device Inc., a joint venture of MicroPort Medical™, held by Earl Intellect Limited and Turbo Heart Limited, for a total of $65 million USD from its own funds. Following the completion of this transaction, Optimum Medical will become a wholly-owned subsidiary of MicroPort Medical™.

 

Optimum Medical owns two subsidiaries, Lombard Medical Limited and Lombard Medical Technologies GmbH (referred to collectively as "Lombard Medical"), primarily engaged in the research, development, production, and sales of endovascular stent graft products for aortic aneurysm repair.

 

Founded in 1994 and headquartered in the UK, Lombard Medical specializes in the development, production, and sales of endovascular stent graft systems for aortic aneurysm repair, with a unique and differentiated product pipeline. Its core products include the Aorfix™ abdominal aortic stent graft system (referred to as "Aorfix™") and the Altura™ abdominal aortic stent graft system (referred to as "Altura™"), providing innovative treatment solutions for patients with complex abdominal aortic diseases.

 

The self-developed Aorfix™ received CE certification from the EU in 2001, FDA approval in the US in 2013, and PMDA approval in Japan in 2014. It is designed for patients with abdominal aortic aneurysms with a neck angle of up to 90 degrees, featuring a unique ring stent and proximal scallop design to accommodate extreme neck angles. Altura™, acquired by Lombard Medical, is a revolutionary 14F ultra-low-profile abdominal aortic stent graft system, CE certified in the EU in 2015. Its globally unique Double-D structure design meets the positioning needs of clinical variations in high and low renal artery anatomies, providing a simple and reliable surgical solution for complex abdominal aortic aneurysm treatment.

 

MicroPort Medical™ currently has three products in the abdominal aortic field: Minos® abdominal aortic stent graft and delivery system, Aegis® bifurcated aortic stent graft and delivery system, and Hercules® bifurcated stent graft and delivery system. Combined with Lombard Medical's product portfolio, this will offer more comprehensive, tailored, and precise medical solutions to a greater number of abdominal aortic disease patients worldwide, establishing a globally competitive product lineup.

 

Lombard Medical has a complete and mature quality management system covering product development, production, and sales, meeting regulatory requirements of CE in the EU, FDA in the US, and PMDA in Japan. With a well-established organizational structure and team covering research and development, clinical registration, production, and sales, Lombard Medical has extensive industry experience. It has cultivated the European market for many years, understanding clearly the product and service requirements of mature markets, and possesses a mature sales network and abundant market and channel resources.

 

As a leading enterprise in the domestic field of aortic and peripheral vascular medical devices, MicroPort Medical™ has 13 marketed products and has maintained a leading market share in the aortic products sector domestically for consecutive years. As of March 2024, its international business covers 34 overseas countries, including Europe, Latin America, and Southeast Asia. Since 2017, MicroPort Medical™ has strategically cooperated with Lombard Medical in product manufacturing, registration, and agency sales, officially launching and actively promoting a globalization development strategy in 2018, with significant synergistic effects between both parties. With this acquisition completed, Lombard Medical will become the business center for MicroPort Medical™ in the European market, further achieving comprehensive and deep coverage of the European market and supporting the expansion into mainstream medical device markets such as the US and Japan. This acquisition ensures the sustained and steady implementation of MicroPort Medical™'s global development strategy and further drives the enhancement of the company's performance.